Compare Freeport-McMoRan Inc (FCX) vs Tempus AI (TEM) Price & Performance

FCX trades at $58.30, down 5.92% over 24 hours, with a neutral technical signal and bearish moving averages. The stock has consistently beaten earnings estimates, with Q2 2026 expected EPS of $0.60. Revenue grew to $25.92B in 2025, with net income of $2.20B and a net margin of 10.34%. The company maintains strong cash flow from operations of $5.61B and a dividend of $0.15 per share payable in August 2026.

FCX presents a favorable outlook with robust earnings performance and analyst consensus pointing to a $72.94 price target, implying significant upside. However, risks include commodity price volatility, high capital expenditures, and debt levels. The stock's current valuation at a P/E of 32.26 may limit near-term gains if growth moderates.

Tempus AI (TEM) trades at $55.62, down 5.1% over 24 hours, with a neutral technical signal and bullish moving average alignment. The company reported Q1 2026 revenue growth and an earnings beat, though it remains unprofitable with a net margin of -22.2%. Recent news highlights FDA clearances and partnerships, while analyst consensus is strongly positive with a $68.50 price target.

The outlook balances high-growth potential in AI-driven healthcare data against significant near-term losses. Investment opportunity lies in Tempus's unique data platform and expanding market reach, but risks include persistent cash burn and competitive pressures. Upside depends on achieving profitability and scaling high-margin segments.